Erschienen in:
28.02.2021 | Letter to the Editor
Fisher syndrome as an immune-related adverse event after using pembrolizumab but not nivolumab
verfasst von:
Kiyotaka Nakamagoe, Takeshi Yamada, Sho Okune, Toshikazu Moriwaki, Akira Tamaoka
Erschienen in:
Acta Neurologica Belgica
|
Ausgabe 5/2021
Einloggen, um Zugang zu erhalten
Excerpt
Antibodies against the programmed cell death 1 (PD-1) receptor, such as pembrolizumab and nivolumab, are associated with immune-related adverse events (irAEs). These drugs are known to cause various autoimmune diseases via abnormal immune responses. Pembrolizumab has been reported to cause immune-mediated neuropathies such as Fisher syndrome (FS) [
1,
2], which is regarded as a subtype of Guillain–Barré syndrome (GBS). FS includes a trilogy of disorders: ataxia of the extremities/body trunk, decreased tendon reflexes, and ocular movement dysfunction. However, there are only a few previous reports of FS developing due to checkpoint immunotherapy including pembrolizumab and nivolumab [
1,
2]. Here, we report the first case in which a patient experienced an irAE such as FS with pembrolizumab, but not after using a different antibody against PD-1 receptor, nivolumab. …
